The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Adalimumab + Methotrexate Effective for Uveitis in JIA

Adalimumab + Methotrexate Effective for Uveitis in JIA

October 2, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Ramanan and collaborators responded that, in pediatric care, oral methotrexate may occasionally be used when the child lacks the ability to cope with weekly subcutaneous injections. “In our trial, we did not specify that children had to be receiving methotrexate subcutaneously in order to avoid restricting our ability to enroll participants and in view of issues of acceptability regarding the subcutaneous route in some children,” they write in correspondence to the editor. “We did not undertake pharmacokinetic studies of either methotrexate or adalimumab in this trial.”

You Might Also Like
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Treating Uveitis with Adalimumab Improves Quality of Life
Also By This Author
  • Rare Disease Sheds Light on the Origins of Lupus

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017 Apr 27;376(17):1637–1646. doi: 10.1056/NEJMoa1614160.
  2. Thorne JE. Adalimumab in the treatment of uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017 Apr 27;376(17):1682–1683. doi: 10.1056/NEJMe1701811.
  3. Peng S, Sun X, Sun M. Letter to the editor: Adalimumab for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017 Aug 24.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: adalimumab, JIA, Juvenile Arthritis (JIA), metho­trexate, Pediatric, Pediatric Rheumatology, Uveitis

You Might Also Like:
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Treating Uveitis with Adalimumab Improves Quality of Life
  • Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)